Introduction to Peptides

• Peptides = small proteins made of 2-50 amino acids (sometimes up to 100)
• Structure: beads on string where each bead = amino acid
• Order of amino acids determines peptide identity and function
• Examples: insulin (blood sugar regulation), oxytocin (pair bonding, socialization)
• Pleotropic effects: single peptide affects multiple cell types/pathways
• Three acquisition categories:
  • FDA-approved prescription peptides
  • Gray market (questionable safety/efficacy)
  • Black market (not recommended - contamination risk)

Peptide Safety and Sourcing

• Safest route: prescription from board-certified physician
• Critical: removal of lipopolysaccharide (LPS) during manufacturing
  • LPS causes immune response
  • Accumulation over time problematic
  • Prescription/compounding pharmacy sources typically LPS-free
• Gray/black market often contain LPS, may not match labels

Category 1: Tissue Rejuvenation and Repair Peptides

BPC-157 (Body Protection Compound)

• Origin: naturally synthesized in gastric juices
• Mechanism:
  • Recognizes injured blood vessels/capillaries
  • Activates eNOS (endothelial nitric oxide synthase)
  • Promotes angiogenesis (new blood vessel formation)
  • Encourages fibroblast migration/growth at injury sites
  • Upregulates growth hormone receptors
• Animal studies: extensive literature since 1993
• Human studies: lacking formal clinical trials
• Dosage: 300-500 micrograms, 2-3x per week, 8-week cycles
• LD50: extremely high (2 grams per kg body weight)
• Administration: subcutaneous or intramuscular injection
• Risks:
  • Tumor growth promotion via increased angiogenesis
  • Upregulates VEGF (vascular endothelial growth factor)
  • Contraindicated for cancer patients
  • Similar mechanism to cancer drug avastin (VEGF inhibitor) but opposite effect

Thymosin Beta-4 and TB-500

• Origin: naturally secreted from thymus gland in children
• TB-500 = truncated version of thymosin beta-4
• Mechanism:
  • Promotes stem cell proliferation
  • Increases extracellular matrix growth
  • Supports tissue stability/rigidity
• Logic: children heal faster due to thymus-derived peptides
• Often combined with BPC-157
• Focus: tissue repair rather than growth promotion

Category 2: Growth Hormone Secretagogue Peptides

Growth Hormone Background

• Secreted from anterior pituitary
• Peak release: early sleep hours
• Decline: ~15% per decade after age 30
• Functions: metabolism, fat loss, muscle growth, ATP production, mood/vitality
• Stimulates IGF-1 release from liver

Type 1 Growth Hormone Secretagogues (GHRH analogs)

Sermorelin

• FDA approved for short stature treatment
• Mimics naturally occurring growth hormone releasing hormone
• Dosage: 200-400 micrograms, 3-5x per week before sleep
• Effects: increases deep sleep, may reduce REM sleep
• Considerations: potential REM sleep depletion

Tesamorelin (Egrifta)

• FDA approved for visceral adiposity reduction in HIV patients
• Longer lasting than sermorelin
• Dosage: typically 3x per week
• Focus: visceral fat reduction

CJC-1295

• Includes DAC (drug affinity complex) for extended duration
• Dosage: 1-2x per week
• Safety concerns: cardiovascular death in clinical trial
• Fluid retention risk
• Less recommended due to safety profile

Type 2 Growth Hormone Secretagogues (Ghrelin pathway)

Ipamorelin

• Increases ghrelin (hunger hormone)
• Dual mechanism: direct GH release + suppresses somatostatin
• Side effects: increased hunger and anxiety
• Improves sleep (primarily deep sleep)

Hexarelin

• Strongest GH stimulator (2-3x other peptides)
• Available by prescription
• Risks:
  • Dramatically increases prolactin
  • Causes receptor desensitization
  • Potential permanent pathway shutdown
  • Fluid retention, malaise

Other GHRPs

• GHRP-2, GHRP-3, GHRP-6
• MK-677 (oral version)
• Common issues: elevated cortisol, prolactin increases

Growth Hormone Peptide Considerations

• Administration: 1.5 hours after eating, 30+ minutes before eating
• Tumor growth risk (indiscriminate tissue growth)
• Body structure changes possible
• Carpal tunnel syndrome risk
• Facial/body morphology changes
• Age consideration: questionable benefit under 30

Category 3: Longevity Peptides

Epithalon (Epitalon)

• Origin: mimics naturally occurring epithalamin from pineal gland
• Pineal gland: produces melatonin + epithalamin
• Functions:
  • Anti-inflammatory effects
  • Telomere length adjustment
  • Circadian rhythm recalibration
• Age-related decline: pineal regression reduces both melatonin and epithalamin
• Animal studies: tumor suppression, increased telomere length
• Human clinical trials: lacking
• Logic: restore age-depleted pineal peptides

Thymosin Beta-4 (longevity context)

• Replaces childhood thymus-derived peptides
• Rationale: thymus disappears with age, healing capacity decreases
• Not direct longevity agent but tissue repair enhancement

Category 4: Vitality Peptides (Mood and Libido)

Melanocortin System Background

• Activated by UV light exposure (eyes/skin)
• Pathway: eyes → hypothalamus → pituitary → melanocyte stimulating hormone
• Natural effects: skin pigmentation, dopamine release, mood enhancement, libido increase
• Seasonal pattern: winter depression → spring/summer vitality

Melanotan Peptides (1-5)

• Melanotan 1: skin darkening only (doesn't cross blood-brain barrier)
• Melanotan 2-5: skin darkening + mood/libido effects (cross blood-brain barrier)
• Common effects: appetite suppression, mood elevation, libido increase
• Side effects: nausea, skin flushing, blood pressure increases
• Melanoma risk: contraindicated for melanoma patients

PT-141 (Vyleesi)

• FDA approved for premenopausal hypoactive sexual desire disorder
• Off-label use in men
• Effects: libido enhancement + skin pigmentation
• Administration considerations: nausea potential

Kisspeptin

• Recently discovered peptide
• Pathway: kisspeptin → GnRH → LH/FSH → testosterone/estrogen
• Functions: puberty activation, reproductive hormone cascade
• Therapeutic uses:
  • Hypothalamic amenorrhea treatment
  • Vitality/libido enhancement
• Kisspeptin antagonists: menopause symptom treatment
• Caution: recently discovered, pleotropic effects not fully understood

General Safety Considerations

• All peptides have pleotropic (multiple) effects
• Tumor growth risk with angiogenic/growth-promoting peptides
• Regular monitoring required: blood tests, tumor screening
• Minimal effective dosing recommended
• Cycling protocols preferred over continuous use
• Professional medical supervision essential
• Quality sourcing critical for safety and efficacy

Current Research Status

• Animal studies: extensive for most peptides
• Human clinical trials: limited for most therapeutic applications
• Anecdotal reports: widespread but uncontrolled
• Regulatory status: mostly off-label prescribing
• Need for formal human studies acknowledged